BAX vs TFX: How Baxter International and Teleflex Incorporated Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and TFX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and TFX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

Teleflex Incorporated designs and manufactures single-use medical devices used in critical care and surgery, sold mainly to hospitals through a large disposable-product installed base. After a portfolio overhaul announced in 2025 and executed through 2026, the continuing business reports in three segments: Vascular Access (the Arrow line of central venous and arterial catheters and related kits), Interventional (complex catheters, the MANTA large-bore closure device, intra-aortic balloon pumps, and the newly acquired Biotronik coronary and peripheral range including the ultrathin Orsiro Mission drug-eluting stent, the PK Papyrus covered stent, and the Pantera Lux and Passeo-18 Lux drug-coated balloons), and Surgical (ligation clips, closure systems, and instruments). The businesses being sold, Acute Care, Interventional Urology (home of UroLift), and OEM contract manufacturing, are reported as discontinued operations.

Full TFX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• TFX drivers: Biotronik vascular intervention integration; Portfolio simplification and capital returns.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For TFX, the Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAX if you believe its drivers more; TFX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and TFX guides.

BAX. Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

TFX. Trailing P/E is not meaningful because GAAP net income is around negative ~$1 billion on divestiture and impairment charges, so the market prices Teleflex off adjusted EPS and forward estimates instead. At roughly ~$140 the shares sit near the upper end of a ~$100 to ~$144 fifty-two week range, and the forward multiple near ~18x is below where large-cap medtech peers typically trade. Second quarter 2026 results are due in early August 2026, and the first set of clean post-divestiture pro forma financials is the number investors are waiting on.

Headline figures (approximate, July 2026): BAX shows revenue (ttm, continuing ops) ~$10.7B, q1 2026 sales ~$2.7B, q1 2026 adjusted eps ~$0.36, market cap ~$11.5B; TFX shows revenue (ttm) ~$2.13B (continuing operations), q1 2026 revenue ~$548M (+32% reported, ~+5% pro forma cc), 2026 adjusted eps guidance ~$6.25 to ~$6.55, 2026 pro forma cc revenue growth ~4.5% to ~5.5%.

BAX and TFX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and TFX exposure against your real portfolio. It is not an investment adviser.